



---

## Product Data Sheet

---

In terms of tumor cell kill, luzopeptin A induced net reductions in the body burdens of L1210 and P388 leukemias following single-drug injections but failed to yield net reductions following multiple-injection therapies [2].

Clinical trial: So far, no clinical study has been conducted.

### References:

[1] Huang, C. H., Mirabelli, C.K., Mong, S., et al. Intermolecular cross-linking of DNA through bifunctional intercalation of an antitumor antibiotic, luzopeptin A (BBM-928A). *Cancer Research* 43, 2718-2724 (1983).

[2] Rose WC, Schurig JE, Huftalen JB, Bradner WT. Experimental antitumor activity and toxicity of a new chemotherapeutic agent, BBM 928A. *Cancer Res.* 1983 Apr;43(4):1504-10.

**Caution: Product has not been fully validated for medical applications. For research use only.**

**Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com**

**Address: 10292 Central Ave. #205, Montclair, CA, USA**